폐암 유전체 검사 시장 예측 : 산업 규모, 점유율, 동향, 기회, 구성요소별, 기술별, 패널 유형별, 샘플 유형별, 최종 사용자별, 지역별, 경쟁 구도(2021-2031년)

The Global Lung Cancer Genomic Testing Market will grow from USD 2.17 Billion in 2025 to USD 3.76 Billion by 2031 at a 9.59% CAGR. Lung cancer genomic testing involves the molecular analysis of tumor tissue or liquid biopsies to identify specific genetic alterations such as EGFR mutations or ALK rearrangements that dictate the selection of targeted therapies. The market is primarily propelled by the clinical transition toward personalized medicine and the stringent regulatory requirement for companion diagnostics to authorize the use of novel oncology drugs.

Key Market Drivers

The Rising Global Incidence and Prevalence of Lung Cancer serves as the foundational catalyst for the genomic testing market, creating an expanding patient pool that necessitates precise molecular diagnosis. As the burden of lung malignancy remains high globally, healthcare systems are increasingly mandating comprehensive biomarker testing for all newly diagnosed patients to determine the most effective management strategies. This volume-driven demand is evidenced by the sheer scale of diagnoses in major markets.

Key Market Challenges

The inconsistent reimbursement landscape for next-generation sequencing constitutes a substantial barrier hampering the growth of the Global Lung Cancer Genomic Testing Market. While clinical guidelines increasingly recommend comprehensive profiling, the lack of uniform payer coverage creates severe economic friction that disconnects clinical availability from patient accessibility. Diagnostic developers face restricted revenue potential as healthcare providers often hesitate to order advanced genomic profiling due to uncertainty regarding payment authorization.

Key Market Trends

The transition from single-gene assays to comprehensive next-generation sequencing (NGS) panels is reshaping the diagnostic standard for lung malignancy, driven by the need to efficiently identify multiple actionable alterations from limited tissue samples. Clinicians are increasingly abandoning iterative single-biomarker testing, which risks tissue exhaustion, in favor of broad genomic profiling that captures co-occurring mutations and complex signatures like tumor mutational burden in a single workflow. This consolidation is critical for matching patients to the growing array of targeted therapies without the latency of sequential testing.

Key Market Players

• QIAGEN NV
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• CENTOGENE N.V.
• BGI Genomics Co. Ltd.
• CeGaT GmbH
• Illumina Inc.
• F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Lung Cancer Genomic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Genomic Testing Market, By Component:

• Products v/s Services

Lung Cancer Genomic Testing Market, By Technology:

• Next Generation Sequencing
• Polymerase Chain Reactions
• Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH)
• Others

Lung Cancer Genomic Testing Market, By Panel Type:

• Single Panel v/s Multi-Gene Panel

Lung Cancer Genomic Testing Market, By Sample Type:

• Tissue Biopsy v/s Liquid Biopsy

Lung Cancer Genomic Testing Market, By End User:

• Academic & Research Institutions
• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Lung Cancer Genomic Testing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Genomic Testing Market.

Available Customizations:

Global Lung Cancer Genomic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Cancer Genomic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Products v/s Services)
  • 5.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others)
  • 5.2.3. By Panel Type (Single Panel v/s Multi-Gene Panel)
  • 5.2.4. By Sample Type (Tissue Biopsy v/s Liquid Biopsy)
  • 5.2.5. By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2025)
• 5.3. Market Map

6. North America Lung Cancer Genomic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Technology
  • 6.2.3. By Panel Type
  • 6.2.4. By Sample Type
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lung Cancer Genomic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Panel Type
      • 6.3.1.2.4. By Sample Type
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Lung Cancer Genomic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Panel Type
      • 6.3.2.2.4. By Sample Type
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Lung Cancer Genomic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Panel Type
      • 6.3.3.2.4. By Sample Type
      • 6.3.3.2.5. By End User

7. Europe Lung Cancer Genomic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Technology
  • 7.2.3. By Panel Type
  • 7.2.4. By Sample Type
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lung Cancer Genomic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Panel Type
      • 7.3.1.2.4. By Sample Type
      • 7.3.1.2.5. By End User
  • 7.3.2. France Lung Cancer Genomic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Panel Type
      • 7.3.2.2.4. By Sample Type
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Lung Cancer Genomic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Panel Type
      • 7.3.3.2.4. By Sample Type
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Lung Cancer Genomic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Panel Type
      • 7.3.4.2.4. By Sample Type
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Lung Cancer Genomic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Panel Type
      • 7.3.5.2.4. By Sample Type
      • 7.3.5.2.5. By End User

8. Asia Pacific Lung Cancer Genomic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Technology
  • 8.2.3. By Panel Type
  • 8.2.4. By Sample Type
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lung Cancer Genomic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Panel Type
      • 8.3.1.2.4. By Sample Type
      • 8.3.1.2.5. By End User
  • 8.3.2. India Lung Cancer Genomic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Panel Type
      • 8.3.2.2.4. By Sample Type
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Lung Cancer Genomic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Panel Type
      • 8.3.3.2.4. By Sample Type
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Lung Cancer Genomic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Panel Type
      • 8.3.4.2.4. By Sample Type
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Lung Cancer Genomic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Panel Type
      • 8.3.5.2.4. By Sample Type
      • 8.3.5.2.5. By End User

9. Middle East & Africa Lung Cancer Genomic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Technology
  • 9.2.3. By Panel Type
  • 9.2.4. By Sample Type
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lung Cancer Genomic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Panel Type
      • 9.3.1.2.4. By Sample Type
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Lung Cancer Genomic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Panel Type
      • 9.3.2.2.4. By Sample Type
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Lung Cancer Genomic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Panel Type
      • 9.3.3.2.4. By Sample Type
      • 9.3.3.2.5. By End User

10. South America Lung Cancer Genomic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Technology
  • 10.2.3. By Panel Type
  • 10.2.4. By Sample Type
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lung Cancer Genomic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Panel Type
      • 10.3.1.2.4. By Sample Type
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Lung Cancer Genomic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Panel Type
      • 10.3.2.2.4. By Sample Type
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Lung Cancer Genomic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Panel Type
      • 10.3.3.2.4. By Sample Type
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lung Cancer Genomic Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. QIAGEN NV
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Agilent Technologies Inc.
• 15.3. Thermo Fisher Scientific Inc.
• 15.4. Quest Diagnostics Incorporated
• 15.5. Laboratory Corporation of America Holdings
• 15.6. CENTOGENE N.V.
• 15.7. BGI Genomics Co. Ltd.
• 15.8. CeGaT GmbH
• 15.9. Illumina Inc.
• 15.10. F. Hoffmann-La Roche Ltd

16. Strategic Recommendations

17. About Us & Disclaimer